Once Upon a Farm, PBC
No SEC Form 4 filings for $OFRM in the last 30 days.
Once Upon a Farm (NYSE: OFRM) reported Q2 2026 net sales up more than 42% year over year to $85.4 million, beating expectations, and raised full-year revenue guidance for a second straight quarter. The company now forecasts 2026 net sales of $325 million to $335 million, citing continued distribution expansion and growth in baby and kids categories.
Once Upon a Farm, PBC (OFRM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ofrm-ex99_1.htm EX-99.1 EX-99.1 Once Upon a Farm Reports Second Quarter 2026 Financial Results Second quarter net sales increased 42% year-over-year to $85 million Raising 2026 net sales outlook to $327 million to $335 million Raising 2026 Adjusted EBITDA outlook to $3
Once Upon a Farm has launched a significant expansion of its product portfolio, introducing new nutrient-dense pouches for children. These new offerings include options like Meat, Meat & Bone Broth, Legume Blends, and Smoothies with Protein & Probiotics, catering to different developmental stages from infants to active kids. The expansion aims to meet parental demand for convenient, organic, and farm-fresh nutrition, moving into refrigerated protein-forward formats.
Over the past 7 days, alphai's AI scored 2 news stories mentioning OFRM (Once Upon a Farm, PBC). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent OFRM coverage spans earnings and financial news.
Guidance lift plus strong Q2 growth suggests improving demand and distribution momentum, supporting bullish near-term positioning.
Raised full-year outlook alongside improving losses and cash position, signaling stronger demand and operating leverage but with margin pressure.
OFRM shows a neutral sentiment with low relevance to broader market movements. Its slight positive sentiment suggests limited immediate trading impact.
Bullish analyst coverage may support upward price movement.
alphai scores every news story that mentions OFRM with an AI model for sentiment and relevance, and aggregates insider trades from Once Upon a Farm, PBC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Once Upon a Farm (NYSE: OFRM) reported Q2 2026 net sales up more than 42% year over year to $85.4 million, beating expectations, and raised full-year revenue guidance for a second straight quarter. The company now forecasts 2026 net sales of $325 million to $335 million, citing continued distribution expansion and growth in baby and kids categories.
4 min readOnce Upon a Farm, PBC (OFRM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ofrm-ex99_1.htm EX-99.1 EX-99.1 Once Upon a Farm Reports Second Quarter 2026 Financial Results Second quarter net sales increased 42% year-over-year to $85 million Raising 2026 net sales outlook to $327 million to $335 million Raising 2026 Adjusted EBITDA outlook to $3
7 min readOnce Upon a Farm has launched a significant expansion of its product portfolio, introducing new nutrient-dense pouches for children. These new offerings include options like Meat, Meat & Bone Broth, Legume Blends, and Smoothies with Protein & Probiotics, catering to different developmental stages from infants to active kids. The expansion aims to meet parental demand for convenient, organic, and farm-fresh nutrition, moving into refrigerated protein-forward formats.
3 min readStifel analyst James Condulis initiated coverage on Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) with a Buy rating and a $21 price target. This article also highlights three other significant analyst initiations for Tuesday, including Goldman Sachs on Once Upon A Farm PBC (NYSE: OFRM), Morgan Stanley on Agomab Therapeutics NV (NASDAQ: AGMB), and Stifel on SpyGlass Pharma, Inc. (NASDAQ: SGP), all with bullish ratings and specific price targets.
4 min read
